My watch list  

Metabolic control of T cell immune response through glycans in inflammatory bowel disease [Immunology and Inflammation]

Our findings demonstrate that metabolic supplementation of mucosal T cells, isolated from patients with active ulcerative colitis (UC), with N -acetylglucosamine (GlcNAc) leads to the enhancement of branched N-glycosylation on the T cell receptor, which was associated with the control of T cell activation and function. These results were validated in “glycoengineered” mouse models with severe colitis. Overall, our results open new avenues for a targeted-specific therapy in inflammatory bowel disease (IBD). The therapeutic use of GlcNAc (either alone or in combination with other antiinflammatory therapies) represents a simple immunomodulatory strategy in IBD, with absence of side effects, low costs, and the possibility of being used as a simple rescue therapy to avoid unnecessary toxic effects and step-up therapies in IBD.

Authors:   Ana M. Dias; Alexandra Correia; Márcia S. Pereira; Catarina R. Almeida; Inês Alves; Vanda Pinto; Telmo A. Catarino; Nuno Mendes; Magdalena Leander; M. Teresa Oliva-Teles; Luís Maia; Cristina Delerue-Matos; Naoyuki Taniguchi; Margarida Lima; Isabel Pedroto; Ricardo Marcos-Pinto; Paula Lago; Celso A. Reis; Manuel Vilanova; Salomé S. Pinho
Journal:   Proceedings of the National Academy of Sciences current issue
Volume:   115
edition:   20
Year:   2018
Pages:   E4651
DOI:   10.1073/pnas.1720409115
Publication date:   15-May-2018
More about Proceedings of the National Academy of Sciences
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE